孤独症谱系障碍的环境风险因素与生物标志物:伞状综述
该伞状综述系统评估了观察性研究Meta分析中孤独症谱系障碍的环境风险因素与生物标志物证据强度。母亲年龄≥35岁、慢性高血压、妊娠期高血压、孕前或孕期超重、子痫前期、孕前抗抑郁药使用及孕期SSRI使用与孤独症风险相关证据令人信服,但生物标志物证据不足。
要点
- 母亲年龄≥35岁、慢性高血压、妊娠期高血压、孕前或孕期超重、子痫前期与孤独症风险相关证据令人信服。
- 孕前抗抑郁药使用和孕期SSRI使用与孤独症风险相关证据令人信服,但可能受母亲精神障碍等混杂因素影响。
- 生物标志物证据稀缺,仅由接近显著性阈值的P值和过少病例数支持。
核心结论
- 令人信服的证据表明母亲年龄和代谢综合征特征等母亲因素与孤独症谱系障碍风险相关。
- 孕期SSRI使用与孤独症风险相关,但可能受混杂因素影响,孕前抗抑郁药使用也令人信服地相关。
- 生物标志物证据稀缺,仅由接近显著性阈值的P值和过少病例数支持。
研究设计与样本
- 伞状综述,系统评估观察性研究的相关Meta分析。
- 提取汇总效应、95%CI、异质性及95%预测区间,检验小研究效应和过度显著性,并在可信度天花板下分析。
- 注册号PROSPERO CRD42018091704。
主要发现
- 仅在子集敏感性分析中,孕前或孕期超重和孕期SSRI使用保留高证据水平;生物标志物证据稀缺。
临床怎么用
- 临床评估孤独症风险时可关注母亲年龄≥35岁、慢性高血压、妊娠期高血压、孕前或孕期超重、子痫前期等母亲因素。
- 孕期SSRI使用与孤独症风险相关,但需考虑母亲精神障碍等混杂因素,不应简单归因。
- 生物标志物证据不足,暂不推荐用于临床风险预测。
局限性
- 生物标志物证据稀缺,仅由接近显著性阈值的P值和过少病例数支持。
- 孕期SSRI使用与孤独症风险的关联可能受其他混杂因素影响,如潜在母亲精神障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous studies have identified potential risk factors and biomarkers for autism spectrum disorder. We aimed to study the strength and validity of the suggested environmental risk factors or biomarkers of autism spectrum disorder. METHODS: We did an umbrella review and systematically appraised the relevant meta-analyses of observational studies. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews for papers published between database inception and Oct 17, 2018, and screened the reference list of relevant articles. We obtained the summary effect, 95% CI, heterogeneity, and 95% prediction intervals. We examined small study effects and excess significance. We did analyses under credibility ceilings. This review is registered with PROSPERO, number CRD42018091704. FINDINGS: 46 eligible articles yielded data on 67 environmental risk factors (544 212 cases, 81 708 787 individuals) and 52 biomarkers (15 614 cases, 15 433 controls). Evidence of association was convincing for maternal age of 35 years or over (relative risk [RR] 1·31, 95% CI 1·18-1·45), maternal chronic hypertension (odds ratio [OR] 1·48, 1·29-1·70), maternal gestational hypertension (OR 1·37, 1·21-1·54), maternal overweight before or during pregnancy (RR 1·28, 1·19-1·36), pre-eclampsia (RR 1·32, 1·20-1·45), prepregnancy maternal antidepressant use (RR 1·48, 1·29-1·71), and maternal selective serotonin reuptake inhibitor (SSRI) use during pregnancy (OR 1·84, 1·60-2·11). Only two associations, maternal overweight before or during pregnancy and SSRI use during pregnancy, retained their high level of evidence under subset sensitivity analyses. Evidence from biomarkers was scarce, being supported by p values close to the significance threshold and too few cases. INTERPRETATION: Convincing evidence suggests that maternal factors, such as age and features of metabolic syndrome, are associated with risk of autism spectrum disorder. Although SSRI use during pregnancy was also associated with such risk when exposed and non-exposed groups were compared, this association could be affected by other confounding factors, considering that prepregnancy maternal antidepressant use was also convincingly associated with higher risk of autism spectrum disorder. Findings from previous studies suggest that one possible confounding factor is underlying maternal psychiatric disorders. FUNDING: None.
引用
- Kim JY, Son MJ, Son CY, et al. Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. Lancet Psychiatry. 2019. PMID: 31230684. doi:10.1016/S2215-0366(19)30181-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。